Preparation and in vitro evaluation of budesonide spray dried microparticles for pulmonary delivery

Scientia Pharmaceutica

Volumn 77, Issue 2, 2009, Pages 419-441

  Naikwade, Sonali ^a   Bajaj, Amrita ^a  

^a SNDT WOMEN S UNIVERSITY   (India)

Author keywords

Budesonide; Drug deposition; Dry powder inhaler; Microparticles; Spray drying

Indexed keywords

BUDESONIDE; CHITOSAN; GELATIN; LACTOSE; MICROSPHERE;

AEROSOL; AIRFLOW; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRY POWDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG; MICROPARTICLE ENZYME IMMUNOASSAY; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SUSTAINED RELEASE FORMULATION; TEMPERATURE; X RAY POWDER DIFFRACTION;

EID: 67149122413     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0901-11     Document Type: Article

References (55)

1. Khilnani G, Banga A. Aerosol therapy. J Indian Acad Clin Med. 2004; 5: 114-123.
2. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation and performance. Respir Med. 2002; 96: 293-304. doi:10.1053/rmed.2001.1276
3. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005; 50: 1209-1227. PMid:16122404 (Pubitemid 46187575)
4. Szafranski W, Cukier A, Ramirez A, Mengaz G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21: 74-81. doi:10.1183/09031936.03.00031402 (Pubitemid 36150304)
5. Larhrib H, Martin GP, Marriott C, Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm. 2003; 257: 283-296. doi:10.1016/S0378-5173(03) (Pubitemid 36507054)
6. Yu Z, Rogers TL, Hu J, Johnston KP, Williams RO. Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid. Eur J Pharm Biopharm. 2002; 54: 221-228. doi:10.1016/S0939-6411(02)00050-54 (Pubitemid 34919397)
7. Steckel H, Muller BW. In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro deposition. Int J Pharm. 1997; 154: 31-37. doi:10.1016/S0378-5173(97)00115-124
8. Steckel H, Brandes HG. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int JPharm. 2004; 278: 187-195. doi:10.1016/j.ijpharm.2004.03.010 (Pubitemid 38670449)
9. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm. 2004; 270: 297-306. doi:10.1016/j.ijpharm.2003. 10.039 (Pubitemid 38077109)
10. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008; 25: 999-1022. doi:10.1007/s11095-007-9475-9481
11. Learoyd TP, Burrows JL, French E, Seville PC. Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm. 2008; 68: 224-234. doi:10.1016/j.ejpb.2007.04.017
12. Schnurch AB. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int J Pharm. 2000; 194: 1-13. doi:10.1016/S0378-5173(99)00365-368
13. Fu J, Fiegel J, Krauland E, Hanesa J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials. 2002; 23: 4425-4433. doi:10.1016/S0142-9612(02)00182-185 (Pubitemid 34888047)
14. Koushik K, Kompella UB. Particle & device engineering for inhalation drug delivery. Drug Deliv Technol. 2004; 4: 40-50.
15. Grenha A, Grainger CI, Dailey LA, Seijo B, Martin GP, Lopez CR, Forbes B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci. 2007; 31: 73-84. doi:10.1016/j.ejps.2007.02.008 (Pubitemid 46660576)
16. Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Technol. 1998; 1: 246-253. doi:10.1016/S1461-5347(98)00059-65 (Pubitemid 28439296)
17. Huang YC, Vieira A, Huang KI, Yeh MK, Chiang CH. Pulmonary inflammation caused by chitosan microparticles. J Biomed Mater Res A. 2005; 75: 283-287. doi:10.1002/jbm.a.30421 (Pubitemid 41463896)
18. Valle MJDJ, Oliveira RJD, Carvalho F, Bastos ML, Navarro AS. Toxicological evaluation of lactose and chitosan delivered by inhalation. J Biomater Sci Polym Ed. 2008; 19: 387-397. doi:10.1163/156856208783721038 (Pubitemid 351311659)
19. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999; 178: 55-65. doi:10.1016/S0378-5173(98)00367-376 (Pubitemid 29074407)
20. Sakagami M, Sakon K, Kinoshita W, Makino Y. Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. J Control Rel. 2001; 77: 117-129. doi:10.1016/S0168-3659(01)00475-478 (Pubitemid 33022621)
21. Grenha A, Seijo B, Lopez CR. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005; 25: 427-437. doi:10.1016/j.ejps. 2005.04.009 (Pubitemid 40853870)
22. Okamoto H, Nishida S, Todo H, Sakakura Y, Iida K, Danjo K. Pulmonary gene delivery by chitosan-pDNA complex powder prepared by a supercritical carbon dioxide process. J Pharm Sci. 2003; 92: 371-380. doi:10.1002/jps.10285 (Pubitemid 36169309)
23. Benita MB, Meijgaarden KEV, Franken KL, Junginger HE, Borchard G, Ottenhoff TH, Geluk A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine. 2004; 22: 1609-1615. doi:10.1016/j.vaccine.2003.09.044 (Pubitemid 38447207)
24. Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, Ilgazli A. Addition of inhaled corticosteroid on combined bronchodilator therapy in patients with COPD. Pulm Pharmacol Ther. 2005; 20: 1-5. PMid:15955716 (Pubitemid 41354268)
25. Cazzola M. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2006; 19: 79-89. doi:10.1016/j.pupt.2005.03.004 (Pubitemid 43052994)
26. Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Rel. 2005; 104: 79-90. doi:10.1016/j.jconrel. 2005.01.003 (Pubitemid 40615237)
27. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol. 1989; 84: 688-700. doi:10.1016/0091-6749(89)90297-90302 (Pubitemid 20008500)
28. Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med. 1999; 160: 157-161. PMid:10390394 (Pubitemid 29326082)
29. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF. Issues in the use of inhaled glucocorticoids. Am Rev Respir Crit Care Med. 1996; 153: 1739-1748. PMid:8665030 (Pubitemid 26187895)
30. Pearlman DS. Preclinical properties of budesonide: Translation to the clinical setting. Clin Ther. 2003; 25: C75-C91. doi:10.1016/S0149-2918(03)80307- 80317 (Pubitemid 37386731)
31. Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K. A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Respirology. 2000; 5: 247-256. doi:10.1046/j.1440- 1843.2000.00256.x (Pubitemid 30743932)
32. Busse W, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998; 101: 457-463. doi:10.1016/S0091-6749(98)70353-70357 (Pubitemid 28208248)
33. Brink KIMvd, Boorsma M, Brekel AJS-vd, Edsbacker S, Wouters EF, Thorsson L. Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol. 2008; 66: 27-35. doi:10.1111/j.1365-2125.2008.03164.x (Pubitemid 351836039)
34. Edsbacker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol. 2002; 88: 609-616. PMid:12086369
35. Tronde A, Gillen M, Lars Borgstrom, Lotvall J, Ankerst J. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol. 2008; 48: 1300-1308. doi:10.1177/0091270008322122
36. Joshi M, Misra A. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization. Int J Pharm. 2001; 223: 15-27. doi:10.1016/S0378-5173(01)00705-710 (Pubitemid 32640874)
37. Shah SP, Misra A. Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance. AAPS PharmSciTech. 2004; 5: article 65. doi:10.1208/pt050465 (Pubitemid 39096043)
38. Sebti T, Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur J Pharm Biopharm. 2006; 63: 51-58. doi:10.1016/j.ejpb.2005.11.003
39. Gupta M, Bhargava HN. Development and validation of a high-performance liquid chromatographic method for the analysis of budesonide. J Pharm Biomed Anal. 2006; 40: 423-428. doi:10.1016/j.jpba.2005.06.038 (Pubitemid 43143349)
40. Hou S, Hindle M, Byron PR. A stability-indicating HPLC assay method for budesonide. J Pharm Biomed Anal. 2001; 24: 371-380. doi:10.1016/S0731-7085(00) 00424-426 (Pubitemid 32121963)
41. Faouzi MA, Dine T, Luyckx M, Brunet C, Gressier B, Cazin M, Wallaert B, Cazin JC. High-performance liquid chromatographic method for the determination of budesonide in bronchoalveolar lavage of asthmatic patients. J Chromatogr. 1995; 664: 463-467. doi:10.1016/0378-4347(94)
42. Naikwade SR, Bajaj AN. Development of validated specific HPLC method for budesonide and characterization of its alkali degradation product. Can J Anal Sci Spect. 2008; 53: 113-122.
43. de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW. Air classifier technology (ACT) in dry powder inhalation Part 1: Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int J Pharm. 2003; 260: 187-200. doi:10.1016/S0378- 5173(03)00250-253 (Pubitemid 36773917)
44. Corrigan DO, Healy AM, Corrigan OI. Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur J PharmBiopharm. 2006; 62: 295-305. doi:10.1016/j.ejpb.2005.09.008 (Pubitemid 43356579)
45. Ungaro F, Rosa GD, Miro A, Quaglia F, Rotonda MIL. Cyclodextrins in the production of large porous particles: Development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006; 28: 423-432. doi:10.1016/j.ejps.2006.05.005 (Pubitemid 44038350)
46. Baxter A, Dillon M, Taylor KDA, Roberts GAF. Improved method for I.R. determination of the degree of N-acetylation of chitosan. Int J Biol Macromol. 1992; 14: 166-169. doi:10.1016/S0141-8130(05)80007-80008
47. Zijlstra GS, Rijkeboer M, Drooge DJ, Sutter M, Jiskoot W, Weert MV, Hinrichs WLJ, Frijlink HW. Characterization of a cyclosporine solid dispersion for inhalation. AAPS J. 2007; 9: E190-E199. doi:10.1208/aapsj0902021 (Pubitemid 47007410)
48. Huang YC, Chiang CH, Yeh MK. Optimizing formulation factors in preparing chitosan microparticles by spray-drying method. J Microencap. 2003; 20: 247-260. doi:10.1016/j.ejps.2006.05.005
49. Heng PWS, Chan LW, Lim LT. Quantification of the surface morphologies of lactose carriers and their effect on the in vitro deposition of salbutamol sulphate. Chem Pharm Bull. 2000; 48: 393-398. doi:10.1080/02652040210162522 (Pubitemid 30187256)
50. Corrigan DO, Healy AM, Corrigan OI. The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. Int J Pharm. 2003; 262: 125-137. doi:10.1016/S0378- 5173(03)00338-347 (Pubitemid 36966700)
51. Prinn KB, Costantino HR, Tracy M. Statistical modeling of protein spray drying at the lab scale. AAPS PharmSciTech. 2002; 3: article 4. doi:10.1208/pt030104 (Pubitemid 41086091)
52. Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, Hall G, Shorr J, Newman SP. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res. 2002; 19: 258-264. doi:10.1023/A:1014482615914
53. Skiba M, Bounoure F, Barbot C, Arnaud P, Skiba M. Development of cyclodextrin microspheres for pulmonary drug delivery. J Pharm Pharmaceut Sci. 2005; 8: 409-418. PMid:16401391 (Pubitemid 41529320)
54. Cerchiara T, Luppi B, Chidichimo G, Bigucci F, Zecchi V. Chitosan and poly(methyl vinyl ether-co-maleic anhydride) microparticles as nasal sustained delivery systems. Eur J Pharm Biopharm. 2005; 61: 195-200. doi:10.1016/j.ejpb. 2005.05.005 (Pubitemid 41427627)
55. Jain SK, Agrawal GP, Jain NK. Evaluation of porous carrier-based floating orlistat microspheres for gastric delivery. AAPS PharmSciTech. 2006; 7: article 90. doi:10.1208/pt070490 (Pubitemid 44782748)